Partial reversal of experimental pulmonary hypertension by phosphodiesterase-3/4 inhibition

European Respiratory Journal

Volumn 31, Issue 3, 2008, Pages 599-610

  Dony, E ^a   Lai, Y J ^a   Dumitrascu, R ^a   Pullamsetti, S S ^a   Savai, R ^a   Ghofrani, H A ^a   Weissmann, N ^a   Schudt, C ^b   Flockerzi, D ^b   Seeger, W ^a   Grimminger, F ^a   Schermuly, R T ^a  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

^b Altana Pharma   (Germany)

Author keywords

Hypertension; Lung; Muscle; Pulmonary; Remodelling; Smooth

Indexed keywords

CYCLIC AMP; MONOCROTALINE; PHOSPHODIESTERASE III; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE IV; PLACEBO; PUMAFENTRINE; UNCLASSIFIED DRUG; NAPHTHYRIDINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; CYCLIC AMP BLOOD LEVEL; DRUG EFFECT; DRUG INHIBITION; DRUG POTENCY; ENZYME INHIBITION; GAS EXCHANGE; HEART HYPERTROPHY; HEMODYNAMICS; IMMUNOHISTOCHEMISTRY; LUNG BLOOD VESSEL; MALE; NONHUMAN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RAT; SMOOTH MUSCLE; SURVIVAL RATE; ANIMAL; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; DRUG ANTAGONISM; HEART RIGHT VENTRICLE HYPERTROPHY; LUNG; PATHOLOGY; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE;

ANIMALS; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 3; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 4; DISEASE MODELS, ANIMAL; HYPERTENSION, PULMONARY; HYPERTROPHY, RIGHT VENTRICULAR; LUNG; MALE; MONOCROTALINE; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; NAPHTHYRIDINES; PHOSPHODIESTERASE INHIBITORS; RATS;

EID: 42949113613     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00002007     Document Type: Article

References (55)

1. Molteni A, Ward WF, Ts'ao CH, Port CD, Solliday NH. Monocrotaline-induced pulmonary endothelial dysfunction in rats. Proc Soc Exp Biol Med 1984; 176: 88-94.
2. Nagaya N, Okumura H, Uematsu M, et al. Repeated inhalation of adrenomedullin ameliorates pulmonary hypertension and survival in monocrotaline rats. Am J Physiol Heart Circ Physiol 2003; 285: H2125-H2131.
3. Rosenberg HC, Rabinovitch M. Endothelial injury and vascular reactivity in monocrotaline pulmonary hypertension. Am J Physiol 1988; 255: H1484-H1491.
4. Schermuly RT, Kreisselmeier KP, Ghofrani HA, et al. Antiremodeling effects of iloprost and the dual-selective phosphodiesterase 3/4 inhibitor tolafentrine in chronic experimental pulmonary hypertension. Circ Res 2004; 94: 1101-1108.
5. Humbert M, Morrell NW, Archer SL, et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43: Suppl. 12, 13S-24S.
6. Christman BW, McPherson CD, Newman JH, et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med 1992; 327: 70-75.
7. Wagner RS, Smith CJ, Taylor AM, Rhoades RA. Phosphodiesterase inhibition improves agonist-induced relaxation of hypertensive pulmonary arteries. J Pharmacol Exp Ther 1997; 282: 1650-1657.
8. MacLean MR, Johnston ED, Mcculloch KM, Pooley L, Houslay MD, Sweeney G. Phosphodiesterase isoforms in the pulmonary arterial circulation of the rat: changes in pulmonary hypertension. J Pharmacol Exp Ther 1997; 283: 619-624.
9. Coulonval K, Bockstaele L, Paternot S, Dumont JE, Roger PP. The cyclin D3-CDK4-p27kip1 holoenzyme in thyroid epithelial cells: activation by TSH, inhibition by TGFb, and phosphorylations of its subunits demonstrated by two-dimensional gel electrophoresis. Exp Cell Res 2003; 291: 135-149.
10. Koyama H, Bornfeldt KE, Fukumoto S, Nishizawa Y. Molecular pathways of cyclic nucleotide-induced inhibition of arterial smooth muscle cell proliferation. J Cell Physiol 2001; 186: 1-10.
11. Paternot S, Coulonval K, Dumont JE, Roger PP. Cyclic AMP-dependent phosphorylation of cyclin D3-bound CDK4 determines the passage through the cell cycle restriction point in thyroid epithelial cells. J Biol Chem 2003; 278: 26533-26540.
12. Cornwell TL, Arnold E, Boerth NJ, Lincoln TM. Inhibition of smooth muscle cell growth by nitric oxide and activation of cAMP-dependent protein kinase by cGMP. Am J Physiol 1994; 267: C1405-C1413.
13. Garg UC, Hassid A. Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest 1989; 83: 1774-1777.
14. Kariya K, Kawahara Y, Araki S, Fukuzaki H, Takai Y. Antiproliferative action of cyclic GMP-elevating vasodilators in cultured rabbit aortic smooth muscle cells. Atherosclerosis 1989; 80: 143-147.
15. Fukumoto S, Koyama H, Hosoi M, et al. Distinct role of cAMP and cGMP in the cell cycle control of vascular smooth muscle cells: cGMP delays cell cycle transition through suppression of cyclin D1 and cyclin-dependent kinase 4 activation. Circ Res 1999; 85: 985-991.
16. Southgate K, Newby AC. Serum-induced proliferation of rabbit aortic smooth muscle cells from the contractile state is inhibited by 8-Br-cAMP but not 8-Br-cGMP. Atherosclerosis 1990; 82: 113-123.
17. Dhaunsi GS, Hassid A. Atrial and C-type natriuretic peptides amplify growth factor activity in primary aortic smooth muscle cells. Cardiovasc Res 1996; 31: 37-47.
18. Hassid A, Arabshahi H, Bourcier T, Dhaunsi GS, Matthews C. Nitric oxide selectively amplifies FGF-2-induced mitogenesis in primary rat aortic smooth muscle cells. Am J Physiol 1994; 267: H1040-H1048.
19. Schermuly RT, Ghofrani HA, Enke B, et al. Low-dose systemic phosphodiesterase inhibitors amplify the pulmonary vasodilatory response to inhaled prostacyclin in experimental pulmonary hypertension. Am J Respir Crit Care Med 1999; 160: 1500-1506.
20. Schermuly RT, Roehl A, Weissmann N, et al. Subthreshold doses of specific phosphodiesterase type 3 and 4 inhibitors enhance the pulmonary vasodilatory response to nebulized prostacyclin with improvement in gas exchange. J Pharmacol Exp Ther 2000; 292: 512-520.
21. Schermuly RT, Krupnik E, Tenor H, et al. Coaerosolization of phosphodiesterase inhibitors markedly enhances the pulmonary vasodilatory response to inhaled iloprost in experimental pulmonary hypertension. Maintenance of lung selectivity. Am J Respir Crit Care Med 2001; 164: 1694-1700.
22. Schermuly RT, Roehl A, Weissmann N, et al. Combination of nonspecific PDE inhibitors with inhaled prostacyclin in experimental pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 2001; 281: L1361-L1368.
23. Muller B, Schmidtke M, Witt W. Action of the stable prostacyclin analogue iloprost on microvascular tone and permeability in the hamster cheek pouch. Prostaglandins Leukot Med 1987; 29: 187-198.
24. Witt W, Müller B. Antithrombotic profile of iloprost in experimental models of in vivo platelet aggregation and thrombosis. Adv Prostaglandin Thromboxane Leukot Res 1987; 17A: 279-284.
25. Schermuly RT, Dony E, Ghofrani HA, et al. Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest 2005; 115: 2811-2821.
26. World Intellectual Property Organization, Flockerzi D. Benzonaphtyridines as bronchial therapeutics. (WO1998/021208). www.wipo.int/pctdb/en/wo.jsp?wo= 1998021208 Date last accessed: April 16, 1999. Date last updated: May 22, 1998.
27. Schermuly RT, Kreisselmeier KP, Ghofrani HA, et al. Chronic sildenafil treatment inhibitsmonocrotaline-induced pulmonary hypertension in rats. Am J Respir Crit Care Med 2004; 169: 39-45.
28. Rose F, Grimminger F, Appel J, et al. Hypoxic pulmonary artery fibroblasts trigger proliferation of vascular smooth muscle cells: role of hypoxia-inducible transcription factors. FASEB J 2002; 16: 1660-1661.
29. Cowan KN, Heilbut A, Humpl T, Lam C, Ito S, Rabinovitch M. Complete reversal of fatal pulmonary hypertension in rats by a serine elastase inhibitor. Nat Med 2000; 6: 698-702.
30. Prie S, Leung TK, Cernacek P, Ryan JW, Dupuis J. The orally active ET(A) receptor antagonist (+)-(S)-2-(4,6-dimethoxy- pyrimidin-2-yloxy)-3-methoxy-3,3- diphe nyl-propionic acid (LU 135252) prevents the development of pulmonary hypertension and endothelial metabolic dysfunction in monocrotaline-treated rats. J Pharmacol Exp Ther 1997; 282: 1312-1318.
31. Sakuma F, Miyata M, Kasukawa R. Suppressive effect of prostaglandin E1 on pulmonary hypertension induced by monocrotaline in rats. Lung 1999; 177: 77-88.
32. Voelkel NF, Tuder R. Interleukin-1 receptor antagonist inhibits pulmonary hypertension induced by inflammation. Ann N Y Acad Sci 1994; 725: 104-109.
33. Olschewski H, Olschewski A, Rose F, et al. Physiologic basis for the treatment of pulmonary hypertension. J Lab Clin Med 2001; 138: 287-297.
34. Olschewski H, Rose F, Grunig E, et al. Cellular pathophysiology and therapy of pulmonary hypertension. J Lab Clin Med 2001; 138: 367-377.
35. Kodama K, Adachi H. Improvement of mortality by long-term E4010 treatment in monocrotaline-induced pulmonary hypertensive rats. J Pharmacol Exp Ther 1999; 290: 748-752.
36. Beavo JA. Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol Rev 1995; 75: 725-748.
37. Manganiello VC, Murata T, Taira M, Belfrage P, Degerman E. Diversity in cyclic nucleotide phosphodiesterase isoenzyme families. Arch Biochem Biophys 1995; 322: 1-13.
38. Torphy TJ. Phosphodiesterase isozymes: molecular targets for novel antiasthma agents. Am J Respir Crit Care Med 1998; 157: 351-370.
39. Lugnier C. Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents. Pharmacol Ther 2006; 109: 366-398.
40. Degerman E, Belfrage P, Newman AH, Rice KC, Manganiello VC. Purification of the putative hormone-sensitive cyclic AMP phosphodiesterase from rat adipose tissue using a derivative of cilostamide as a novel affinity ligand. J Biol Chem 1987; 262: 5797-5807.
41. Bornfeldt KE, Campbell JS, Koyama H, et al. The mitogen-activated protein kinase pathway can mediate growth inhibition and proliferation in smooth muscle cells. Dependence on the availability of downstream targets. J Clin Invest 1997; 100: 875-885.
42. Bornfeldt KE, Krebs EG. Crosstalk between protein kinase A and growth factor receptor signaling pathways in arterial smooth muscle. Cell Signal 1999; 11: 465-477.
43. Paternot S, Coulonval K, Dumont JE, Roger PP. Cyclic AMP-dependent phosphorylation of cyclin D3-bound CDK4 determines the passage through the cell cycle restriction point in thyroid epithelial cells. J Biol Chem 2003; 278: 26533-26540.
44. Kothapalli D, Stewart SA, Smyth EM, Azonobi I, Pure E, Assoian RK. Prostacylin receptor activation inhibits proliferation of aortic smooth muscle cells by regulating cAMP response element-binding protein- and pocket protein-dependent cyclin A gene expression. Mol Pharmacol 2003; 64: 249-258.
45. Klemm DJ, Watson PA, Frid MG, et al. cAMP response element-binding protein content is a molecular determinant of smooth muscle cell proliferation and migration. J Biol Chem 2001; 276: 46132-46141.
46. Clapp LH, Finney P, Turcato S, Tran S, Rubin LJ, Tinker A. Differential effects of stable prostacyclin analogs on smooth muscle proliferation and cyclic AMP generation in human pulmonary artery. Am J Respir Cell Mol Biol 2002; 26: 194-201.
47. Wharton J, Davie N, Upton PD, Yacoub MH, Polak JM, Morrell NW. Prostacyclin analogues differentially inhibit growth of distal and proximal human pulmonary artery smooth muscle cells. Circulation 2000; 102: 3130-3136.
48. Fischmeister R, Castro LR, Bi-Gerges A, et al. Compartmentation of cyclic nucleotide signaling in the heart: the role of cyclic nucleotide phosphodiesterases. Circ Res 2006; 99: 816-828.
49. Celermajer DS, Cullen S, Deanfield JE. Impairment of endothelium- dependent pulmonary artery relaxation in children with congenital heart disease and abnormal pulmonary hemodynamics. Circulation 1993; 87: 440-446.
50. Giaid A, Yanagisawa M, Langleben D, et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 1993; 328: 1732-1739.
51. Herve P, Launay JM, Scrobohaci ML, et al. Increased plasma serotonin in primary pulmonary hypertension. Am J Med 1995; 99: 249-254.
52. Seibert AF, Thompson WJ, Taylor A, Wilborn WH, Barnard J, Haynes J. Reversal of increased microvascular permeability associated with ischemia-reperfusion: role of cAMP. J Appl Physiol 1992; 72: 389-395.
53. Stelzner TJ, Weil JV, O'Brien RF. Role of cyclic adenosine monophosphate in the induction of endothelial barrier properties. J Cell Physiol 1989; 139: 157-166.
54. Suttorp N, Hippenstiel S, Fuhrmann M, Krull M, Podzuweit T. Role of nitric oxide and phosphodiesterase isoenzyme II for reduction of endothelial hyperpermeability. Am J Physiol 1996; 270: C778-C785.
55. Suttorp N, Ehreiser P, Hippenstiel S, et al. Hyperpermeability of pulmonary endothelial monolayer: protective role of phosphodiesterase isoenzymes 3 and 4. Lung 1996; 174: 181-194.